Company intelligence / Profile preview

Atavistik Bio

Cambridge, Massachusetts, United Statesatavistikbio.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Atavistik Bio has established a pipeline of precision allosteric small molecule therapeutics targeting serious unmet needs in oncology. Its lead candidate, ATV-1601—a selective allosteric inhibitor for solid tumors with AKT1 E17K mutations—is expected to enter clinical trials in early 2025. The company’s AMPS™ platform enables rapid identification of novel functional allosteric sites across challenging target classes. No clinical results are available yet as the programs are preclinical/IND-enabling.

Therapeutic areas: Oncology
Modalities: Small molecules (precision allosteric small molecule therapeutics)
Industry: Biotech

Drug pipeline

5 assets

ATV-1601

4 more assets in the full pipeline.

Partnerships

Pfizer – research collaboration leveraging AMPS™ platform for two undisclosed targets

Beyond the preview

Go deeper on Atavistik Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atavistik Bio.